GN
GNS.LSE Genus PLC
- Market cap
- GBX 1.54B
- P/E
- 5.6x
- P/B
- 2.05x
- ROE
- 37.2%
- Dividend yield
- 1.36%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is GNS.LSE undervalued?
Graham numberGNS.LSE trades 28.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genus PLC fundamental analysis
No fundamental analysis for Genus PLC yet.
Genus PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and…
Full company profileGenus PLC financial statements
Genus PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 459M | 470M | 489M | 551M | 574M | 593M | 690M | 669M | 673M | 658M |
| Gross Profit | 171M | 183M | 186M | 212M | 232M | 226M | 239M | 179M | 673M | 658M |
| Operating Income | 40.6M | 41.8M | 44.3M | 45.4M | 61.5M | 56.6M | 40.5M | 6.40M | 42.4M | 87.3M |
| EBITDA | 64.8M | 36.4M | 71.8M | 82.5M | 95.4M | 95.6M | 87.4M | 73.7M | 93.7M | 128M |
| Net Income | 32.8M | 42.7M | 7.80M | 35.3M | 47.3M | 40.9M | 33.3M | 7.90M | 19.3M | 285M |
| EPS | 0.53 | 0.69 | 0.12 | 0.54 | 0.72 | 0.62 | 0.50 | 0.12 | 0.29 | 4.25 |
| Balance Sheet | ||||||||||
| Total Assets | 798M | 789M | 804M | 855M | 851M | 1.02B | 1.01B | 1.03B | 899M | 1.02B |
| Total Liabilities | 396M | 370M | 317M | 361M | 354M | 446M | 440M | 485M | 423M | 252M |
| Shareholders' Equity | 399M | 417M | 488M | 496M | 498M | 579M | 569M | 548M | 476M | 767M |
| Cash & Short-term Investments | 26.5M | 31.6M | 30.5M | 41.3M | 46.0M | 38.8M | 36.3M | 42.5M | 48.0M | 43.7M |
| Total Debt | 138M | 138M | 110M | 144M | 152M | 224M | 232M | 291M | 266M | 108M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 34.6M | 43.2M | 33.4M | 65.8M | 67.5M | 34.3M | 50.4M | 29.8M | 67.2M | 90.5M |
| Capital Expenditure | 13.4M | 17.8M | 17.1M | 35.4M | 33.8M | 50.9M | 35.2M | 24.7M | 18.6M | 12.5M |
| Free Cash Flow | 21.2M | 25.4M | 16.3M | 30.4M | 33.7M | -16.6M | 15.2M | 5.10M | 48.6M | 78.0M |
| Ratios | ||||||||||
| ROE | 8.2% | 10.2% | 1.6% | 7.1% | 9.5% | 7.1% | 5.8% | 1.4% | 4.1% | 37.2% |
| ROA | 4.1% | 5.4% | 1.0% | 4.1% | 5.6% | 4.0% | 3.3% | 0.8% | 2.1% | 28.0% |
| Net Profit Margin | 7.1% | 9.1% | 1.6% | 6.4% | 8.2% | 6.9% | 4.8% | 1.2% | 2.9% | 43.4% |
| Debt to Equity | 0.35x | 0.33x | 0.23x | 0.29x | 0.30x | 0.39x | 0.41x | 0.53x | 0.56x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genus PLC dividends
- Dividend yield
- 1.36%
- Forward dividend
- 0.33 GBX
- Payout ratio
- 7.6%
- Ex-dividend date
- Nov 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | GBP 21.7M | 0.32 | 7.6% |
| 2025 | GBP 21.1M | 0.32 | 109.3% |
| 2024 | GBP 21.0M | 0.32 | 265.8% |
| 2023 | GBP 21.0M | 0.32 | 63.1% |
| 2022 | GBP 20.9M | 0.32 | 51.1% |
| 2021 | GBP 19.5M | 0.30 | 41.2% |
| 2020 | GBP 18.3M | 0.28 | 51.8% |
| 2019 | GBP 16.8M | 0.26 | 215.4% |
| 2018 | GBP 14.9M | 0.24 | 34.9% |
| 2017 | GBP 13.5M | 0.22 | 41.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genus PLC
- Insiders 0.77%
- Institutions 74.50%
- Public & others 24.74%
- Shares outstanding 64.5M
- Free float 61.6M
Genus PLC company profile
- Company name
- Genus PLC
- Ticker
- GNS.LSE
- ISIN
- GB0002074580
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,921
- Fiscal year end
- June
- Address
- Matrix House, Basingstoke, United Kingdom, RG21 4FF
- Phone
- 44 1256 347 100
- Website
- genusplc.com
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Genus PLC management
9- Mr. Jorgen KokkeCEO & Executive Director · born 1968
- Mr. Andrew Paul RussellCFO & Executive Director · born 1974
- Dr. Matt CulbertsonChief Operating Officer
- Dr. Elena RiceHead of R&D and Chief Scientific Officer
- Ms. Lucie Mary Katja GrantGroup General Counsel & Company Secretary
- Mr. Mark BirriChief Corporate Development Officer
- Ms. Angelle R. Rosata SPHRChief Human Resources Officer
- Mr. Jim LowChief Operating Officer of Genus ABS
- Ms. Janet DuaneGroup Financial Controller